和誉-B(02256.HK)：口服小分子KRAS G12D抑制剂ABSK141的IND获NMPA批准
ABBISKOABBISKO(HK:02256) Ge Long Hui·2025-12-24 00:09

Core Viewpoint - The company He Yu-B (02256.HK) has received approval from the National Medical Products Administration (NMPA) in China for its clinical trial application of the oral, highly active, and selective small molecule KRAS G12D inhibitor ABSK141, aimed at treating patients with advanced solid tumors carrying the KRAS G12D mutation [1] Group 1 - The drug ABSK141 is specifically designed for patients with advanced solid tumors that have the KRAS G12D mutation [1] - The approval from NMPA marks a significant milestone for the company in advancing its oncology pipeline [1]